Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
29.34
+0.94 (3.31%)
Dec 20, 2024, 4:00 PM EST - Market closed
Akero Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Akero Therapeutics stock have an average target of 46.83, with a low estimate of 30 and a high estimate of 65. The average target predicts an increase of 59.61% from the current stock price of 29.34.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 18, 2024.
Analyst Ratings
The average analyst rating for AKRO stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
Buy | 5 | 5 | 5 | 5 | 3 | 3 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 9 | 9 | 9 | 9 | 8 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Citigroup | Citigroup | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +121.54% | Nov 18, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +70.42% | Nov 18, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +70.42% | Nov 11, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +70.42% | Sep 17, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +70.42% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.97
from -2.89
EPS Next Year
-4.83
from -3.97
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | 76.0M | |||
Avg | n/a | n/a | 37.0M | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -3.18 | -4.06 | -4.07 | |||
Avg | -3.97 | -4.83 | -4.78 | |||
Low | -4.18 | -6.12 | -6.36 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.